Selank for anxiety: what six Phase 2 trials actually show in 2026.

What Selank is — TKPRPGP, tuftsin, and why intranasal

Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s as a stable analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) released from the Fc fragment of immunoglobulin G during phagocytosis. The native tuftsin sequence is biologically active but unstable; the Pro-Gly-Pro C-terminal tail in Selank slows enzymatic degradation and dramatically extends its functional half-life in tissue compartments.

The plasma half-life of intact Selank, after intranasal administration, is short — on the order of minutes — but downstream signalling effects on neurotrophins and neurotransmitter turnover persist for hours [Kost 2001]. The intranasal route was chosen for two reasons. First, oral peptides of this size and structure are substantially degraded before reaching systemic circulation. Second, intranasal delivery exploits the olfactory and trigeminal pathways that allow some fraction of the dose to reach central nervous system tissue without first traversing the blood-brain barrier.

Selank sits inside the broader category we cover in the peptides worth knowing in 2026 — the established-to-speculative tiering of the class. It has been approved in the Russian Federation since 2009 for the treatment of generalized anxiety disorder (GAD) [Zozulia 2008]. It has not been submitted for FDA or EMA review and is not approved in North America, the United Kingdom, or the European Union. The clinical data summarised below is the evidence that supported Russian approval — and the evidence that Western regulators have, so far, not been asked to evaluate.

Mechanism — GABA, enkephalinase, BDNF, serotonin turnover

The mechanistic story for Selank is unusually multi-modal for a seven-amino-acid peptide. Four distinct signals appear in the preclinical literature.

Enkephalinase inhibition. Kost and colleagues demonstrated that Selank dose-dependently inhibits the enzymatic hydrolysis of endogenous enkephalins in plasma [Kost 2001]. Enkephalins are the body's own opioid-like peptides; inhibiting the enzymes that degrade them produces a sustained elevation of endogenous opioid tone without administering an exogenous opioid. This is the most distinctive feature of the molecule, and the most plausible candidate for its non-sedating anxiolytic signal.

GABA-A modulation. Kasian and colleagues, working in a chronic-mild-stress rat model, reported that Selank affects the specific binding of GABA at GABA-A receptors and produces a synergistic effect when co-administered with diazepam [Kasian 2017]. The mechanism appears to be allosteric rather than direct agonism — Selank does not displace benzodiazepines from their canonical binding site — which is consistent with the observed absence of sedation, motor impairment, and physical dependence in clinical use.

BDNF upregulation. Inozemtseva and colleagues, working in Wistar rats, showed that a single intranasal dose of Selank produced measurable upregulation of BDNF messenger RNA and, subsequently, BDNF protein in the hippocampus [Inozemtseva 2008]. (The paper's full abstract is not available on PubMed; the specific timing windows commonly cited in secondary literature — mRNA at ~3 hours, protein at ~24 hours — derive from the Russian-language full text and have not been independently re-analysed in English.) The hippocampus is one of two adult-neurogenesis sites in the mammalian brain and is consistently implicated in anxiety and mood disorders; BDNF is the most-replicated molecular signal linking neurotrophic activity to antidepressant and anxiolytic response. Whether this rodent neurotrophin signal translates to humans has not been tested.

Serotonin turnover. A later rat study demonstrated that Selank accelerates the turnover of serotonin (5-HT) in the brain stem, measured by the ratio of 5-hydroxyindoleacetic acid (5-HIAA, the principal serotonin metabolite) to 5-HT itself [Semenova 2009]. Related work by the same group using non-PCPA-depleted animals found similar turnover signals in the hypothalamus [Semenova 2010]. Importantly, this is a metabolism signal, not a synthesis signal — Selank appears to accelerate the use of existing serotonin pools rather than to elevate raw 5-HT, which is mechanistically different from how SSRIs operate. Both findings are in rodent models; human serotonin-turnover data does not yet exist.

The honest mechanistic summary: four plausible, partially independent contributions to an anxiolytic effect. None of them have been mapped in detail in human tissue. The preclinical fingerprint is consistent with the clinical reports — non-sedating, non-dependence-forming, partial cognitive activation alongside anxiety reduction — but the species-to-species translation has not been rigorously characterised.

Selank is the only published anxiolytic peptide where the mechanism story is multi-modal — GABA, enkephalinase, BDNF, and 5-HT turnover all show signal. Whether that's a strength or a sign nobody has nailed down the dominant pathway is an open question.

The Zozulia 2008 trial — Selank vs medazepam

The anchor trial in the Selank literature is Zozulia and colleagues, published in 2008 in the Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova (the Korsakov Journal of Neurology and Psychiatry) and indexed on PubMed only as a Russian-language entry with an English abstract [Zozulia 2008]. The trial enrolled 62 patients meeting ICD-10 criteria for generalized anxiety disorder or neurasthenia, and randomised them to one of two arms:

• 30 patients received intranasal Selank 0.15% solution, administered to a total daily dose in the range of 1,800–2,700 μg/day, for 14 days.
• 32 patients received oral medazepam at 30 mg/day for the same 14-day duration.

Medazepam (also marketed as Rudotel) is a long-acting benzodiazepine used in Russian and continental European psychiatry as an anxiolytic. It is mechanistically a direct GABA-A positive allosteric modulator at the benzodiazepine site, which makes it a defensible active comparator for a peptide whose proposed GABA mechanism is allosteric and indirect.

Primary endpoint instruments were the Hamilton Anxiety Rating Scale (HAM-A), the Zung Self-Rating Anxiety Scale, and the Clinical Global Impressions scale, assessed at baseline and at end of treatment. The authors also measured plasma enkephalin-degrading enzyme activity to map the mechanism into the clinical population.

The published readout: anxiolytic efficacy was comparable across the two arms on the principal scales, with Selank additionally producing what the authors described as antiasthenic and mild psychostimulant effects — a cognitive-activation signal not seen in the medazepam arm. Sedation, motor impairment, and the typical benzodiazepine side-effect cluster were observed only in the medazepam group. The change in HAM-A score reported across the Selank cohort sits in the range of roughly 22–39% from baseline, depending on subgroup and which day of treatment is anchored on. This is the figure most commonly cited in downstream literature.

The other Phase 2 readouts

Around the anchor trial, the Russian psychiatry literature contains several additional Phase 2-class human studies of Selank in anxiety-spectrum populations. Most are open-label, none are multi-centre by Western standards, and few have been formally translated. The pattern across them is consistent rather than explosive.

Uchakina and colleagues, in the same 2008 issue of the Korsakov journal, reported that Selank produced measurable immunomodulatory changes in patients with anxiety-asthenic disorders alongside the symptom-scale reduction, suggesting that the mechanism extends to cytokine signalling under stress [Uchakina 2008]. A follow-up rapid-vs-slow-response analysis published in European Psychiatry (conference proceedings, 2012) characterised the time-to-response distribution within Selank responders — a meaningful fraction showed early improvement within the first week, while a second cluster showed slower onset across the full 14-day window [Medvedev 2012].

Sokolov and colleagues, working downstream of the Kost mechanism finding, demonstrated in a comparative mouse study (BALB/c versus C57Bl/6 strains) that Selank's anxiolytic behavioural effect in the open-field test was tightly correlated with measured prolongation of plasma leu-enkephalin half-life — and absent in the strain in which Selank failed to alter enkephalinase activity [Sokolov 2002]. Parallel work in patients with anxiety and phobic disorders showed shortened plasma enkephalin half-life and reduced total enkephalinase activity in GAD specifically, but not in panic disorder or agoraphobia. Together these are the closest the literature gets to a mechanistic biomarker bridging the preclinical story to the clinical population.

Aggregated across the available trials, the readout is internally consistent. Symptom reduction on HAM-A, Zung, and CGI; effect comparable in magnitude to oral benzodiazepine comparators; absence of sedation, withdrawal, or rebound anxiety on discontinuation; partial cognitive activation rather than impairment. The principal weakness is the same across every trial — small samples, single sites, Russian-language reporting, and an investigator group substantially overlapping across the entire literature.

How it actually compares to benzodiazepines

The most useful framing for Selank is the comparison to benzodiazepines, because that is the comparison the trials themselves were powered to make.

On symptom reduction — the central question for any anxiolytic — the head-to-head trial showed comparable effect on the principal scales. Selank does not appear to be a more powerful anxiolytic than medazepam; the case for it rests on what it does not do.

On sedation and motor impairment, Selank produced substantially less. Benzodiazepines impair psychomotor performance in a dose-dependent way that contributes to falls and motor-vehicle-accident risk in older patients and to cognitive complaints across all ages. The Selank trials report cognitive activation rather than impairment in the same population.

On dependence and withdrawal, the case is more nuanced. Benzodiazepine physical dependence develops over weeks to months of continuous dosing, and withdrawal includes rebound anxiety, sleep disruption, and in severe cases seizures. No equivalent dependence syndrome has been characterised for Selank in the published literature, and the proposed mechanism (allosteric GABA modulation plus enkephalinase inhibition) is not the same pharmacology that drives benzodiazepine dependence. The honest version of this claim: the absence of dependence reports in 14-day Phase 2 trials does not establish absence of dependence with chronic use, because chronic-use data does not exist. The mechanism makes the dependence case unlikely. The trial design does not test it.

On onset, benzodiazepines act within an hour. The Selank trials report symptom improvement detectable by day seven and maximal by day fourteen, which is closer to an SSRI-class onset than a benzodiazepine-class onset. This is a meaningful clinical difference. Selank is not a rescue medication; it is a 14-day treatment course. For the standard first-line options Selank would be sitting alongside, the anxiety & mood hub walks through SSRIs, ketamine, psilocybin, and the lifestyle layer.

On access and regulation, the gap is unbridgeable outside Russia. Selank is a prescription medication in the Russian Federation. It is not a regulated medication in North America. Any product sold in the United States or Canada as "Selank" is sourced from research-chemical or compounding channels, with the quality, purity, and concentration variability that channel implies.

Side-effect profile, taken seriously

The published Selank side-effect profile, across the available Phase 2 trials, is unusually quiet. The most consistent reports are:

• Local nasal irritation — the most commonly reported adverse effect, related to the intranasal delivery rather than the molecule itself. Usually mild and self-limiting.
• Mild headache — reported in a minority of patients, usually within the first three days.
• Cognitive activation — variably reported as positive (the antiasthenic signal) or as a mild side effect when patients describe over-activation or difficulty sleeping at the upper dosing range. Where sleep disturbance is the limiting issue, the magnesium sleep RCT data is the cleaner first-line lever.
• Absence of the benzodiazepine cluster — no sedation, no motor impairment, no rebound anxiety on discontinuation in 14-day trials.

What the side-effect profile does not tell us is the long-term picture. Every published Selank trial in humans is short — 14 days is the standard window, with a few protocols extending to 30. Chronic-dosing data over months and years does not exist in the peer-reviewed literature. The molecule is a peptide with a pleiotropic mechanism, and the prudent assumption is that effects emerging only with chronic use have simply not been measured. The stress-physiology layer that often underlies chronic anxiety — cortisol dysregulation, HPA-axis overactivation — is a separate but adjacent concern covered in the cortisol and stress-fat piece.

The honest evidence gaps

Six honest gaps shape any responsible read of the Selank evidence base. For broader context on where Selank sits within the peptide class, the reference index covers mechanism, evidence tier, and approval status across compounds.

One — Western replication. No multi-centre, non-Russian Phase 2 or Phase 3 trial has been published. Without independent replication, the entire case for Selank rests on a single investigator network in a single country. This is not unusual for peptides developed in Russia in the 1990s, but it is a real limitation on extrapolation.

Two — sample sizes. The largest single-arm count in the published trials is in the low double digits. By the standards of SSRI or SNRI evidence development, this is hypothesis-generating, not confirmatory. The effect sizes reported are large enough that the sample sizes are not statistically lethal, but they are not robust to meta-analytic re-evaluation in the way Western anxiolytic data is.

Three — placebo control. The anchor trial used an active comparator (medazepam) rather than a placebo arm. This is defensible as an equivalence design but does not establish the absolute magnitude of effect against the placebo response, which in GAD trials is consistently 30–40%. A placebo-controlled Selank trial in a Western population would resolve this question. It has not been done.

Four — chronic dosing. Every trial is short. No published data describes Selank use over months or years. The absence of dependence reports in 14-day data is informative; the absence of any other chronic-dosing finding is uninformative because it has not been studied.

Five — comparison to first-line Western anxiolytics. No head-to-head trial of Selank against an SSRI, SNRI, buspirone, or pregabalin exists. The benzodiazepine comparator was chosen for regulatory and mechanistic reasons; it does not tell us how Selank compares to the medications that an English-speaking GAD patient would actually be prescribed today.

Six — quality control in the off-label market. Outside Russia, Selank reaches end-users through research-chemical suppliers and compounding pharmacies of variable quality. Independent third-party assays of products sold as "Selank" outside the Russian prescription supply chain are not published with any consistency. The molecule that has been studied in trials is not necessarily the molecule in any given vial.

A tiered framework

We do not write protocols. We write frameworks that you take to a clinician. The framework for Selank assumes that you have read the gaps above and are factoring them into the decision.